This paper, published in the online Practice Update journal Renal Cell Carcinoma this week, provides real world efficacy data for axitinib (Inlyta) in second-line treatment and beyond for metastatic renal cell carcinoma. The article suggests that the real world efficacy data for axitinib is similar to that seen in clinical trials, with a median overall survival of 16.4 months and median progression-free survival of 8.3 months.

Read more here